Cargando…

Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial

OBJECTIVES: Investigating the effect of prognostic factors in a multistate framework on survival in a large population of patients with osteosarcoma. Of interest is how prognostic factors affect different disease stages after surgery, with stages of local recurrence (LR), new metastatic disease (NM)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hazewinkel, Audinga-Dea, Lancia, Carlo, Anninga, Jakob, van de Sande, Michiel, Whelan, Jeremy, Gelderblom, Hans, Fiocco, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900028/ https://www.ncbi.nlm.nih.gov/pubmed/35246418 http://dx.doi.org/10.1136/bmjopen-2021-053083

Ejemplares similares

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
por: Smeland, Sigbjørn, et al.
Publicado: (2019)

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment(†)
por: Whelan, J. S., et al.
Publicado: (2015)

Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy
por: Calaminus, Gabriele, et al.
Publicado: (2019)

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
por: Lancia, Carlo, et al.
Publicado: (2019)

Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma
por: Lancia, Carlo, et al.
Publicado: (2019)

Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial
por: Musta, Eni, et al.
Publicado: (2022)

Neural Networks for Survival Prediction in Medicine Using Prognostic Factors: A Review and Critical Appraisal
por: Kantidakis, Georgios, et al.
Publicado: (2022)

Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
por: Strauss, Sandra J., et al.
Publicado: (2018)

Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity
por: Lancia, Carlo, et al.
Publicado: (2018)

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
por: Marina, Neyssa M, et al.
Publicado: (2016)

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center
por: Evenhuis, Richard E., et al.
Publicado: (2021)

Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma
por: Spreafico, Marta, et al.
Publicado: (2021)

Single‐Center Experience with Ifosfamide Monotherapy as Second‐Line Treatment of Recurrent/Metastatic Osteosarcoma
por: Verschoor, Arie Jan, et al.
Publicado: (2019)

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report
por: Kager, Leo, et al.
Publicado: (2016)

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients
por: Buddingh, Emilie P., et al.
Publicado: (2012)

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
por: McTiernan, Anne, et al.
Publicado: (2012)

Osteosarcoma: Evolution of Treatment Paradigms
por: Jaffe, Norman, et al.
Publicado: (2013)

Mendelian randomization analysis of the causal impact of body mass index and waist-hip ratio on rates of hospital admission
por: Hazewinkel, Audinga-Dea, et al.
Publicado: (2022)

Osteosarcoma: Lessons Learned and Future Avenues
por: Puri, Ajay, et al.
Publicado: (2013)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
por: Bielack, Stefan S., et al.
Publicado: (2015)

A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma
por: Mctiernan, Anne, et al.
Publicado: (2004)

Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients
por: Heemelaar, Julius C., et al.
Publicado: (2023)

Sensitivity to missing not at random dropout in clinical trials: Use and interpretation of the trimmed means estimator
por: Hazewinkel, Audinga‐Dea, et al.
Publicado: (2022)

The Genetics of Osteosarcoma
por: Martin, Jeff W., et al.
Publicado: (2012)

Case report: challenges in monitoring and treatment of anthracycline induced cardiotoxicity in young adults with osteosarcoma
por: Heemelaar, Julius C., et al.
Publicado: (2022)

"Osteosarcoma"
por: Winfield Reyes, Martín Ricardo
Publicado: (1993)

Osteosarcoma
por: Philip, T, et al.
Publicado: (2001)

Follow-up practices for high-grade extremity Osteosarcoma
por: Rothermundt, Christian, et al.
Publicado: (2016)

Low‐grade osteosarcoma is predominant in gnathic osteosarcomas: A report of seven cases of osteosarcoma of the jaw
por: Sasaki, Aya, et al.
Publicado: (2021)

Gene expression array profile of human osteosarcoma
por: Leonard, P, et al.
Publicado: (2003)

Enhanced osteosarcoma growth produced in rats by osteosarcoma allografts.
por: Geddes-Dwyer, V., et al.
Publicado: (1977)

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
por: Tian, Hailong, et al.
Publicado: (2023)

Osteosarcoma : revisión bibliográfica (
por: Cortés Hernández, José Antonio
Publicado: (1995)

Osteosarcoma : revisión bibliográfica
por: Cortés Hernández, José Antonio
Publicado: (1995)

Osteosarcoma canino /
por: Avalos Barra, Citlalli Yeyetzi
Publicado: (2010)

Chemotherapy for osteosarcoma.
por: Souhami, R. L.
Publicado: (1989)

Telengiectactic osteosarcoma
por: Idiculla, Jose Joy, et al.
Publicado: (2011)

Osteosarcoma of the rib
por: Lim, WY, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_td4guq8s7fgmiod2991fur358h